Clinical trials
Immunization clinical trials
Below are recruiting immunization clinical trials, each written for real people, not researchers. We’re tracking 973 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07234019RecruitingPhase 2
Rituximab plus anti-CD38 antibody for ITP
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07221643Recruiting
Carotenoids, skin health and immune aging study
This study looks at how natural compounds in the skin called carotenoids relate to immune changes as we age. It compares younger and older healthy adults to understand aging better.
Redwood City, CaliforniaAges 18 years+ - NCT06685887RecruitingPhase 2
Chemo, Immunotherapy, and Heated Belly Chemo for Stomach Cancer Spread
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07206758RecruitingPhase 1
Study of SHR-2173 for immune thrombocytopenia (ITP)
This study tests a new medication called SHR-2173 for people with immune thrombocytopenia (ITP) whose platelet count is low and who have already tried steroids without success. The goal is to see if this drug can help raise platelet counts and reduce bleeding risk.
Wuhan, HubeiAges 18 years+ - NCT07206823Recruiting
Romiplostim N01 plus rituximab for ITP that didn't respond to oral TPO-RA
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
Suzhou, JiangsuAges 14 years+ - NCT07195006Recruiting
Malnutrition in pregnancy and child growth study
This study looks at how nutrition during pregnancy affects the health of mothers and babies, including gut health and growth. It compares women with low nutrition to those with healthy nutrition.
HarareAges 18 years+ - NCT06941948Recruiting
Sleep and immune system in lung cancer
This study looks at how sleep problems affect your body's immune response to lung cancer. It aims to find links between sleep and the tumor environment, which could help improve treatment.
ShanghaiAges 18–70 - NCT05667610Recruiting
Immune and gut diet study for peanut-allergic children
This trial studies whether an immune-supportive diet can improve gut health (gut permeability) in children with confirmed peanut or tree-nut allergy. If you join, the researchers will use allergy testing and gut-related diet approaches to see whether symptoms and gut measures change.
AmsterdamAges 3–17 - NCT07156084RecruitingPhase 4
HPV vaccine long-term effect study for young adults
This study checks if one dose of the 9-valent HPV vaccine given at ages 9-11 still protects you 6 years later. It is for people who only had that single dose and no other HPV shots.
Québec, QuebecAges 15–17 - NCT07130799Recruiting
Monitoring immune response in severe abdominal infections with fungal risk
This trial monitors a marker of immune function (monocyte HLA-DR) in patients with severe abdominal infections that may lead to fungal infections. It aims to see if this marker can help guide treatment.
Vandœuvre-lès-NancyAges 18 years+ - NCT07133659RecruitingPhase 4
New starting dose of avatrombopag for immune thrombocytopenia
This study tests a modified starting dose of avatrombopag, a medication that helps raise platelet counts, in adults with immune thrombocytopenia (ITP) who have not responded well to first-line steroid treatments. The goal is to see if this new dosing is effective and safe.
BaghdadAges 18 years+ - NCT07127705Recruiting
How stem cells and immune cells respond to a supplement
This trial tests how a supplement affects your stem cells and immune cells over time. It may help researchers understand if the supplement supports your body's natural defenses.
Klamath Falls, OregonAges 18–75 - NCT07095127RecruitingPhase 2
Testing NVG-2089 for immune thrombocytopenia
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Washington D.C., District of ColumbiaAges 18–80 - NCT06853444RecruitingPhase 1/Phase 2
ESG206 for adults with hard-to-treat ITP
This trial tests a new drug called ESG206 for adults with immune thrombocytopenia (ITP) whose platelet counts remain very low despite previous treatments like steroids or IVIG. The goal is to see if ESG206 can safely help raise platelet levels and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT06900920RecruitingPhase 3
Study of TQB3473 tablets for adults with chronic immune thrombocytopenia
This trial tests an investigational tablet called TQB3473 against placebo for adults with primary immune thrombocytopenia (ITP) that has lasted at least a year and hasn't responded well to standard treatments. The goal is to see if the drug can safely increase platelet counts and reduce bleeding risk.
Hefei, AnhuiAges 18–75 - NCT07065968RecruitingPhase 2
Teriflunomide and steroids for new immune thrombocytopenia
This trial tests if adding teriflunomide to high-dose dexamethasone helps adults newly diagnosed with immune thrombocytopenia (ITP) who have low platelets or bleeding. It aims to find a safer, more effective way to raise platelet counts.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07071103RecruitingPhase 2
Low-dose radiation and immunotherapy for resistant solid tumors
This trial tests a combination of low-dose radiation to the intestines and immunotherapy for people whose cancer has stopped responding to standard treatments including immunotherapy. It may offer a new option when other therapies have failed.
Shantou, GuangdongAges 18–80 - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65 - NCT07059000RecruitingPhase 3
Study of a drug for adults with chronic ITP
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
Los Angeles, CaliforniaAges 18–70 - NCT07063199RecruitingPhase 2
Anti-CD38 antibody for older adults with hard-to-treat ITP
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 60 years+ - NCT05442710RecruitingPhase 2
Immune cell treatment for recovery from severe septic shock
This trial tests an immune-cell treatment given outside the body to help people recover from septic shock, a life-threatening reaction to infection. It aims to improve survival and organ recovery in patients who are still very ill despite standard care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06992128RecruitingPhase 2
Romiplostim plus steroids for newly diagnosed ITP
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07047053Recruiting
Shingles vaccine study for people with autoimmune diseases
This study looks at how well the shingles vaccine works in people with autoimmune inflammatory diseases. Researchers want to make sure the vaccine provides good protection for patients whose immune systems are affected by their condition or treatment.
ParisAges 18 years+ - NCT07043946RecruitingPhase 1/Phase 2
Budoprutug for immune thrombocytopenia
This trial tests a new drug called budoprutug for people with immune thrombocytopenia (ITP), a condition where your immune system attacks your own platelets, causing low counts. The study aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
PlovdivAges 18 years+
Hear when a new Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunization?
- Yes. Clin2 currently lists 973 recruiting immunization studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunization trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunization trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.